Compare BridgeBio Pharma Inc (BBIO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Royal Caribbean Cruises Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Royal Caribbean Cruises Ltd trades at $307.5 (market cap $82.38B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 5× BridgeBio Pharma Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.62% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RCL | |
|---|---|---|
Market Cap | $16.61B | $82.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $365.84 |
52-Week Low | $47.29 | $246.71 |
Enterprise Value | $18.16B | $105.02B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Royal Caribbean Group (RCL) trades at $320, down 0.17% on the day, with a bullish technical signal and strong fundamental momentum. The stock is supported by robust earnings beats, with Q2 2026 EPS of $4.21 exceeding the $3.98 estimate, and a consensus analyst price target of $343.09 implying upside. Recent news highlights strong demand, fleet expansion, and a $1.25 billion senior notes offering to fund growth, while cash flow trends show improving operational strength.
The outlook for RCL remains positive, driven by record bookings, pricing power, and strategic investments, though risks include geopolitical impacts on European itineraries, high debt levels, and premium valuations. Investors should weigh the company's solid execution against macroeconomic and industry-specific headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
